| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 530388150 | Human | 25 |
| 20100010202 | Human antibodies derived from immunized xenomice - Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof. | 01-14-2010 |
| 20100056764 | Antibodies against human NKG2D and uses thereof - The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies. | 03-04-2010 |
| 20100168400 | Superagonistic Anti-CD28 Antibodies - The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising
| 07-01-2010 |
| 20110118446 | METHODS AND COMPOSITIONS FOR ANTIBODY PRODUCTION - Methods and compositions for antibody production are described herein to produce human antibodies in immunodeficient mice. Particularly mice are implanted with human fetal thymus cells or human thymus and human liver tissue and human hematopoietic cells followed by immunization with an antigen. Immunization involves exposure to any of a variety of antigens including tumor antigens, microbial antigens, viral antigens and/or cytokines and growth factor. | 05-19-2011 |
| 20120046452 | ANTIBODY-MEDIATED REJECTION INHIBITOR - A purpose of the present disclosure to achieve transplantation from ABO-incompatible donors and inhibition of autoimmune disease, for example, without significantly impairing defense mechanisms. | 02-23-2012 |
| 20120108796 | Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI) - Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided. | 05-03-2012 |
| 20130046081 | FULLY HUMAN MONOCLONAL ANTIBODY TO VEGF, PREPARATION METHOD AND USE THEREOF - The present invention provides a fully human anti-VEGF monoclonal antibody, the preparation method and use thereof. The fully human anti-VEGF monoclonal antibody is obtained by using antibody phage display technology, which has higher antibody affinity and stronger capacity for inhibiting tumor cell proliferation in comparison with humanized antibody bevacizumab, and can be used to prepare anti-tumor medicines. | 02-21-2013 |
| 20130072664 | HUMAN MONOCLONAL ANTIBODY HAVING FAT-REDUCING EFFECT - Purified polypeptide is proposed, the amino acid sequence of which is essentially identical to the amino acid sequence of SEQ ID NO:1 and SEQ ID NO:3, the polypeptide binding low density lipoproteins (LDL) and/or oxidized LDL (oxLDL), in particular LDL cholesterol and/or oxidized LDL cholesterol (oxLDL cholesterol). | 03-21-2013 |
| 20130109845 | FULLY HUMAN INFLUENZA M2 SPECIFIC ANTIBODIES | 05-02-2013 |
| 20130158238 | Compositions and Methods for the Therapy and Diagnosis of Influenza - The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection. | 06-20-2013 |
| 20130190481 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure. | 07-25-2013 |
| 20130274450 | BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF - Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. | 10-17-2013 |
| 20140155582 | NOVEL ANTI-HUMAN NGF ANTIBODY - [Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. | 06-05-2014 |
| 20140179904 | PROTEIN PURIFICATION USING HCIC AND ION EXCHANGE CHROMATOGRAPHY - The present invention provides methods for purifying proteins. In particular, the methods employ a two-step non-affinity chromatography process without the use of an in-process tangential flow filtration step. | 06-26-2014 |
| 20140200332 | LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNF-ALPHA ACTIVITY IS DETRIMENTAL - A method of treating TNFα disorders is described, wherein the method comprises administering a low dose amount of a TNFα inhibitor. | 07-17-2014 |
| 20140275493 | ANTI-TFPI ANTIBODY VARIANTS WITH DIFFERENTIAL BINDING ACROSS PH RANGE FOR IMPROVED PHARMACOKINETICS - Antibodies are disclosed that bind to and inhibit the anti-coagulant function of TFPI and have a lower affinity for TFPI at pH 6.0 than at pH 7.4. The lower affinity at pH 6 improves circulating half-life (T½) due to reduced target mediated clearance, a process by which an antibody/antigen complex is endocytosed and trafficked to the lysosome where both components are degraded. The lower affinity at pH 6.0 results in disruption of the complex prior to lysosome targeting and allows for re-circulation of the antibody. Specific modifications to antibody binding by histidine residue substitution are disclosed along with methods of use. | 09-18-2014 |
| 20140296493 | METHOD OF TREATING DEPRESSION USING A TNFa ANTIBODY - The invention describes methods of treating depression comprising administering a TNFα antibody, such as a human TNFα antibody. | 10-02-2014 |
| 20150094455 | Human Antibody Specific for IL-1alpha - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 04-02-2015 |
| 20150141623 | PROTEIN PURIFICATION METHODS TO REDUCE ACIDIC SPECIES - The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of charge variants, aggregates, and fragments of a protein of interest, as well as host cell proteins, present in purified preparations by applying particular chromatography conditions during such protein purification. | 05-21-2015 |
| 20150329588 | PROTEIN PURIFICATION USING DISPLACEMENT CHROMATOGRAPHY - Disclosed herein are compositions and methods for the isolation and purification of proteins from a sample. In particular, the present invention relates to compositions and methods for isolating and purifying proteins incorporating a displacement chromatographic step. The present invention is also directed toward pharmaceutical compositions comprising one or more antibodies purified by a method described herein. | 11-19-2015 |
| 20150344564 | Viral Inactivation During Purification of Antibodies - Described herein are methods for isolating and purifying antibodies from a sample matrix. One aspect of the present disclosure is directed to viral reduction/inactivation of samples generated in the various steps of antibody purification. In a particular aspect, methods herein employ an acidification step followed by one or more chromatography steps. The chromatography steps can include one or more of the following chromatographic procedures: ion exchange chromatography, affinity chromatography, and hydrophobic interaction chromatography. | 12-03-2015 |
| 20150344580 | Human Monoclonal Antibodies Against Human Chemokine Receptor CCR7 - Aspects of this invention include fully human antibodies or fragments thereof that bind specifically to human CCR7 receptor. Such antibodies or fragments thereof can be used to treat disorders involving over function of the CCR7 receptor, including cancers. Other uses include detection of human CCR7 receptor in biological samples for diagnostic or evaluative purposes. Fully human antibodies against human CCR7 therefore can be used to diagnose disorders involving CCR7. Further, antibodies of this invention can be useful for treating disorders involving CCR7 by inhibiting binding of native chemokines to the CCR7, and thereby decrease effects of those chemokines. Anti-CCR7 antibodies of this invention can also be used as specific targeting agents to bring toxic agents to CCR7-expressing cells, to inhibit chemotaxis, and therefore can be effective therapeutic agents. | 12-03-2015 |
| 20160096881 | MEANS AND METHODS FOR PRODUCING HIGH AFFINITY ANTIBODIES - The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures. | 04-07-2016 |
| 20160114036 | COMPOSITION FOR STABILIZING PROTEIN AND PHARMACEUTICAL FORMULATION COMPRISING THE SAME - The present invention relates to a composition for stabilizing TNFα-binding protein exhibiting physiological activity, and more specifically, to a composition for stabilizing protein including basic amino acid and sugar and/or ammonium salt, a pharmaceutical formulation including the same, and a method for stabilizing TNFα-binding protein. The formulation including basic amino acid; and sugar and/or ammonium salt according to the present invention effectively inhibits aggregation, denaturation and oxidation of TNFα-binding protein used for treating various diseases, for example, an anti-TNF-alpha antibody, such that the protein is capable of being preserved and stored for a long time, which is widely usable and effective in a medical field using TNFα-binding protein, for example, an anti-TNF-alpha antibody. | 04-28-2016 |
| 20160251441 | ANTIBODY PURIFICATION | 09-01-2016 |
